Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002 May;180:396-404. QUESTION: In patients with depressive disorders, is venlafaxine more effective and tolerable than other antidepressants?
Main results
32 studies (5562 patients) were included. Sample sizes ranged from 28 to 382 patients (mean 179 patients). The length of follow up ranged from 4 to 48 weeks (mean 10 wks). When studies were pooled, the mean severity of depressive symptoms was lower for venlafaxine than for other antidepressants. When grouped by drug class, venlafaxine was more effective than selective serotonin reuptake inhibitors (SSRIs) but did not differ from tricyclic agents (TCAs) or other drugs. A similar treatment effect was seen for response and remission rates.Venlafaxine did not differ from other antidepressants for total dropout rates.
Conclusions
In patients with depressive disorders, venlafaxine is more effective than selective serotonin reuptake inhibitors. Dropout rates do not differ between venlafaxine and other types of antidepressants. 
Pooled odds ratio (CI) NNT (CI)
Response *SSRI = selective-serotonin reuptake inhibitor; TCA = tricyclic agent. CI defined in glossary. Response defined as ≥ 50% improvement from baseline. Remission defined as depression rating scale score below a predefined threshold. †Not significant.
COMMENTARY
Clinical guidelines and systematic reviews typically hold that available antidepressants are equally efficacious and effective. The meta-analysis by Smith et al, however, found that venlafaxine led to greater reduction in depressive symptoms and greater probability of good clinical outcome than did prescription of other antidepressants in general or SSRI antidepressants in particular. Because the meta-analysis included data from traditional efficacy studies, some questions remain regarding generalisation to everyday practice. Firstly, did the selection process for these efficacy trials create an inadvertent bias in favour of venlafaxine? Given current medication-use patterns, previous unsuccessful treatment with SSRI drugs may have been more common than unsuccessful treatment with venlafaxine.
Secondly, does the Hamilton Depression Rating Scale (HDRS) measure the treatment effects that matter most to patients? The authors' point would be stronger if other measures (such as patients' global ratings of improvement or quality of life measures) also showed an advantage for venlafaxine. The specific symptoms included in the HDRS (eg, insomnia rather than hypersomnia) might bias comparisons of venlafaxine with other classes of drugs.
Thirdly, how might results be affected by the treatment structure of a randomised efficacy trial? Such trials typically limit dose adjustment and prohibit medication switches. Data collection ignores patients discontinuing protocol treatment. In actual practice, switching antidepressant medication is common and not an indication of treatment failure. Practicing clinicians ask, "Which medication should I try first?" rather than, "Which medication must I stick with regardless of the outcome?"
As the authors correctly point out, their finding of an efficacy advantage for venlafaxine should be confirmed by subsequent studies, including more generalised patient populations, a broader range of outcome measures, and more typical treatment conditions. Pending such studies, this meta-analysis strengthens previous suggestions that venlafaxine offers some efficacy advantage over SSRI antidepressants. 
